Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Eurocommercial Properties H1 2026 profit after tax jumps 85% to €78.1 million

Eurocommercial Properties H1 2026 profit after tax jumps 85% to €78.1 million

BitgetBitget2026/11/03 13:14
  • Eurocommercial Properties’ first-half 2026 IFRS profit after taxation jumped 85% year over year to €78.1 million.
  • The improvement primarily reflected the non-recurrence of Italy’s €50 million substitute tax and lower deferred tax on property investments.
  • Total revenue rose to €138.7 million, while net property income increased to €98.4 million.
  • April’s acquisition of Avion Shopping in Sweden represented a total investment of €111 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurocommercial Properties NV published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss